Net profit in Q4 increased by over 437%. Hengdian Group DMEGC Magnetics turns its performance around against the winds | Interpretations
①Hengdian Group DMEGC Magnetics experienced explosive performance in Q4, contributing nearly half of the annual profits; ②The company's performance exceeded some Brokerage expectations; ③The Lithium Battery Business contributed significantly, mainly through gross margin recovery in core business; ④The company aims for double growth in revenue and profits by 2025.
Another overseas L in the month, Beijing Easpring Material Technology signed a long-term supply agreement worth 14 billion yuan with LGES | Quick Read Announcement.
① Beijing Easpring Material Technology has signed another overseas L, a long-term supply agreement worth 14 billion yuan with LGES; ② Last Monday, the company announced a framework supply agreement of 0.017 million tons for lithium battery cathode material with "old friend" SK On.
NBTM New Materials Group's full control of Shanghai Fuchi is changing. Shenzhen Yuanzhi "refuses to exit"? | Quick reading of the announcement.
① Compared to the previous announcement, NBTM New Materials Group's acquisition this time has reduced the shareholding ratio by 15%, indicating that its plan to fully control Shanghai Fuchi has faced obstacles; ② Currently, the valuation of 100% equity of Shanghai Fuchi is approximately 1.35 billion yuan, a decrease of 0.25 billion yuan compared to the valuation in September 2023; ③ According to the capital increase agreement at that time, if qualification listing is not completed within 5 years, Shanghai Fuchi should pay back the repurchase price to Yuanzhi Xinghuo in cash.
The Shanghai Aladdin Biochemical Technology Co.,Ltd fundraising project has been repeatedly delayed, raising market concerns, as the leading biological reagent company faces construction difficulties.
① This is not the first time that Shanghai Aladdin Biochemical Technology Co., Ltd.'s three major projects have not met expectations. As early as March 8, 2024, Aladdin had issued a similar announcement regarding the delay of fundraising projects. ② Currently, some domestic enterprises are rapidly seizing the market and expanding their revenue scale mainly through representing foreign brands, even resorting to Low Stock Price competition, which has lowered the competition threshold in the Industry.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Henan Yicheng New Energy lists its subsidiary for sale, with liabilities exceeding 0.2 billion and receivables likely difficult to recover | Quick read announcement
① Henan Yicheng New Energy transferred 100% of its shares in Hengrui. Previously, Pingmei Longji had been "relieved of burden" by the listed company; ② Due to significant losses in the Solar Cells business of Pingmei Longji and other reasons, Henan Yicheng New Energy expects a net loss attributable to the parent company of 0.6 billion to -0.7 billion yuan in 2024.
101843152 : it crashed